liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Next generation pan-cancer blood proteome profiling using proximity extension assay
KTH Royal Inst Technol, Sweden.
KTH Royal Inst Technol, Sweden.
KTH Royal Inst Technol, Sweden.
KTH Royal Inst Technol, Sweden.
Show others and affiliations
2023 (English)In: Nature Communications, E-ISSN 2041-1723, Vol. 14, no 1Article in journal (Refereed) Published
Abstract [en]

Comprehensive and scalable proteomic profiling of plasma samples can improve the screening and diagnosis of cancer patients. Here, the authors use the Olink Proximity Extension Assay technology to characterise the plasma proteomes of 1477 patients across twelve cancer types, and use machine learning to obtain a protein panel for cancer classification. A comprehensive characterization of blood proteome profiles in cancer patients can contribute to a better understanding of the disease etiology, resulting in earlier diagnosis, risk stratification and better monitoring of the different cancer subtypes. Here, we describe the use of next generation protein profiling to explore the proteome signature in blood across patients representing many of the major cancer types. Plasma profiles of 1463 proteins from more than 1400 cancer patients are measured in minute amounts of blood collected at the time of diagnosis and before treatment. An open access Disease Blood Atlas resource allows the exploration of the individual protein profiles in blood collected from the individual cancer patients. We also present studies in which classification models based on machine learning have been used for the identification of a set of proteins associated with each of the analyzed cancers. The implication for cancer precision medicine of next generation plasma profiling is discussed.

Place, publisher, year, edition, pages
NATURE PORTFOLIO , 2023. Vol. 14, no 1
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-197562DOI: 10.1038/s41467-023-39765-yISI: 001037322100032PubMedID: 37463882OAI: oai:DiVA.org:liu-197562DiVA, id: diva2:1795818
Note

Funding Agencies|Knut and Alice Wallenberg Foundation; SciLifeLab amp; Wallenberg Data Driven Life Science Program [KAW 2020.0239]; Swedish Research Council [2018-05973, 2020-06175]

Available from: 2023-09-11 Created: 2023-09-11 Last updated: 2023-09-11

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Zhong, Wen
By organisation
Division of Cell BiologyFaculty of Medicine and Health Sciences
In the same journal
Nature Communications
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 193 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf